MILabs’ advanced in vivo imaging enables groundbreaking research
Mouse imaging reveals how Parkinson’s begins in the gut
Parkinson’s Disease (PD) pathology may begin in the gut and travel from there to the brain long before a patient becomes symptomatic. Researchers at Johns Hopkins School of Medicine imaged this mechanism of PD with U-SPECT after administering α-synuclein preformed fibrils (PFF) into the stomach of mice. A month later, the animals showed clear PD symptoms and loss of dopamine transporters.
123I-FP-CIT SPECT mouse image acquired 7 months after injecting the vehicle (control) and α-synuclein preformed fibrils (PFF) gastrointestinal-injection.
World’s first mouse 223Ra radiotherapy imaging
223Ra is the first approved α-particle emitter for cancer therapy and is an effective treatment for castrate resistant prostate cancer patients with bone metastatic disease. However, mechanisms of action and factors that affect 223Ra distribution are poorly understood. Researchers at Washington University and Johns Hopkins, utilized MILabs’ high-sensitivity SPECT to quantify 223Ra distributions in vivo which allows to elucidate radiobiological effects and to optimize protocols.
Longitudinal in vivo comparison with PET-imaging validates MILabs’ CT-guided fluorescence tomography (FLT)
Researchers at RWTH Aachen and the Academy of Sciences in Prague, used a dual-modality probe (DY750-HPMA-64Cu), detectable by both FLT and PET imaging. By directly comparing FLT to PET as the gold standard, they proved the robustness of MILabs’ FLT quantification. This study demonstrated the applicability of hybrid FLT-CT imaging for accurate biodistribution assessment of tracers.
Quantification of fluorescence and PET intensities (half-life time corrected) exhibited similar percentages of injected dose (%ID) in organs and tumor. At later time points, the PET signals decreased stronger due to the decay of the radioactive tracer and were not detectable in most organs after 144 h, marked by *, whereas the fluorescence signals were still detectable.
From India to Bolivia: MILabs further strengthens dominance in translational imaging market
An increasing number of in-vivo preclinical researchers is discovering the synergistic translational imaging advantages of MILabs scalable PET/SPECT/Optical/CT platform. New product acquisitions include:
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.